We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

FDA Uneasy About Long-Form Zyprexa Side Effect

Law360 (February 4, 2008, 12:00 AM EST) -- The bad news continues to pile up for Eli Lilly & Co., with the U.S. Food and Drug Administration issuing a word of caution about the excessive sedation connected to a long-form version of the company's popular schizophrenia drug Zyprexa.

On Monday, the FDA posted an analysis of Zyprexa Adhera, revealing a mixed bag regarding the effectiveness and potential side effects of the injectable formulation.

“FDA agrees that the sponsor has shown that Olanzapine Depot is effective in both the acute and maintenance treatment of schizophrenia,”...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.